Update Management of Atopic Dermatitis
Background: Atopic dermatitis (AD) is a chronic recurrent skin disease that is very complex due to impaired skin barrier function in the form of xerosis, chronic eczematous lesions, and itching, commonly found in infants and children. Pathogenesis is thought to be the interaction of genetic factors, immune dysfunction, epidermal barrier dysfunction, and the role of the environment and infectious agents. Approach the disease by performing etiopathogenesis algorithms, clinical manifestations, diagnosis, and treatment. Based on the 2013 Asia-Pacific consensus, AD management guidelines using the 5-pillar principle have long been used. Currently, the European consensus in 2018 has developed new guidelines for AD management. Purpose: To provide an updated treatment for AD. Review: The ethiopathogenesis of AD is influenced by genetics, skin barrier disorders, and immune response disorders. Updated management of the European consensus in 2018 includes education, avoidance of precipitating factors, psychosomatic counseling, optimization of skin barrier function with moisturizers, anti-inflammatory and antimicrobial administration, allergen-specific immunotherapy, complementary and alternative drugs, phototherapy, and controlling the itch-scratch cycle with anti-itch in pediatric and adult AD patients. AD may affect patients’ quality of self-esteem. In general, patients expect higher. Conclusion: AD affects the psychosocial aspects of patients. Updated management of AD adequately improves the quality of life.
Simon D, Wollenberg A, Renz H, Simon HU. Atopic dermatitis: collegium international allergologicum (CIA) update 2019. Int Arch Allergy Immunol. 2019;178:207-18.
Simpson EL, Leung DYM, Eichenfield LF, Boguniewics M. Atopic Dermatitis. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, Orringer JS, editors. Fitzpatrick's Dermatology. 9th ed. New York: McGraw-Hill Company; 2019. p. 363-81.
Bylund S, Kobyletzki LBV, Svalstedt M, Svensson A. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol. 2020;100:320-9.
Oledzka EK, Czarnecka M, Baran A. Epidemiology of atopic dermatitis in Europe. J Drug Assess. 2019;8(1):126-8.
Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32:657-82.
Guttman-Yassky E, Waldman A, Ahluwalia J, Ong PY, Eichenfield LF. Atopic dermatitis: Pathogenesis. Seminars in Cutaneous Medicine and Surgery. 2017; 36:100-103.
Brar K, Leung DYM. Recent considerations in the use of recombinant interferon-gamma for biological therapy of atopic dermatitis. Expert Opin Biol Ther. 2016;16(4):5007-14.
McAleer MA, O'Regan GM, Irvine AD. Atopic dermatitis.In: Bolognia JL, Schaffer J, Cerroni L, editors. Dermatology. 4th ed. New Haven: Elsevier Limited; 2018. p. 208-27.
Katoh N, Ohya Y, Ikeda M, Ebihara T, Katayama I, Saeki H, et al. Japanese guidelines for atopic dermatitis 2020. Allergo J Int. 2020;1-14.
Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol.2018;32:850-78.
Ertam I, et al. The Turkish guideline for the diagnosis and management of atopic dermatitis-2018. Turkderm. 2018;52:6-23.
Miyano K, Tsunemi Y. Current treatments for atopic dermatitis in Japan. J Dermatol. 2021;48:140-51.
Lee DE, Clark AK, Tran KA, Shi VY. New and emerging targeted systemic therapies: a new era for atopic dermatitis. J of Dermatol Treat. 2018;29(4):364-74.
Wolverton SE. Comprehensive Dermatologic Drug Therapy. 4th Ed. Philadelphia: Elsevier; 2021.
Elmariah SB. Adjunctive management of itch in atopic dermatitis. Dermatol Clinic. 2017:1-22.
Lee JH, Yun SJ, Lee JB, Lee SC. Therapeutic efficacy and safety of methotrexate in moderate to severe atopic dermatitis: a retrospective study of Korean patients at tertiary referral hospital. Ann Dermatol. 2020;32(5):402-8.
Aljebab F, Choonara I, Conroy S. Systematic review of the toxicity of long-course oral corticosteroids in children. JPLOS One. 2017;12(1):1-18.
Fuggle NR, Bragoli W, Mech B, Mahto A, Glover M, Martinez AE, et al. the adverse effect profile of oral azathioprine in pediatric atopic dermatitis, and recommendations for monitoring. J Am Academy Dermatol. 2015;72(1):108-14.
Ferruci S, Casazza G, Angileri L, Tavecchio S, Germiniasi F, Berti E. Clinical response and quality of life in patients with severe atopic dermatitis treated with dupilumab: a single-center real-life experience. J Clin Med. 2020;9(791):1-10.
Mansour NO, Mohamed AA, Hussein M, Eldemiry E, Daifalla A, Hassanin S. The impact of vitamin D supplementation as an adjuvant therapy on clinical outcomes in patients with severe atopic dermatitis: a randomized controlled trial. Pharmacol Res Perspect. 2020;679:1-8.
Teo CWL, Tay SHY, Tey HL, Ung YW, Yap WN. Vitamin E in atopic dermatitis: from preclinical to clinical studies. J Dermatol. 2020;1-12.
Yan F, Li F, Liu J, Ye S, Zhang Y, Jia J, et al. The formulae and biologically active ingredients of Chinese herbal medicines for the treatment of atopic dermatitis. J Biomed Pharmacother.2020;127:1-16.
Atakan N, Yalcin B, Ozkaya E, Kucuk OS, Ozturkcan S,Salman A, et al. Atopic dermatitis diagnosis and treatment consensus report. Turkderm-Turk Arch Dermatol Venereol.2022;56(2):86-121.
Jorge MT, Maria OSJ, Onate V, Pedro CMC, Altea EM, Amparo PF. Comparison of phototherapy in pediatric and adult patients. Actas Dermosifiliogr. 2020;111(1):41-6.
Copyright (c) 2024 Berkala Ilmu Kesehatan Kulit dan Kelamin
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
- Copyright of the article is transferred to the journal, by the knowledge of the author, whilst the moral right of the publication belongs to the author.
- The legal formal aspect of journal publication accessibility refers to Creative Commons Atribusi-Non Commercial-Share alike (CC BY-NC-SA), (https://creativecommons.org/licenses/by-nc-sa/4.0/)
- The articles published in the journal are open access and can be used for non-commercial purposes. Other than the aims mentioned above, the editorial board is not responsible for copyright violation
The manuscript authentic and copyright statement submission can be downloaded ON THIS FORM.